Compound Kushen Injection Reduces Severe Toxicity and Symptom Burden Associated With Curative Radiotherapy in Patients With Lung Cancer

• Published in: Journal of the National Comprehensive Cancer Network Vol. 21; no. 8; p. 821
• Main Authors: Liu, Jie, Yu, Qingxi, Wang, Xin Shelley, Shi, Qiuling, Wang, Jun, Wang, Fan, Ren, Simeng, Jin, Jiayue, Han, Baojin, Zhang, Wenzheng, Su, Xueyao, Yuan, Shuanghu, Lin, Hongsheng
• Format: Journal Article
• Language: English
• Published: United States 01.08.2023
• Subjects: lung cancer; symptom burden; Compound Kushen Injection; radiation injury
• ISSN: 1540-1413
• DOI: 10.6004/jnccn.2023.7036

Radiotherapy (RT) causes adverse events for which there are no effective treatments. This study investigated the clinical benefits of compound Kushen injection (CKI) in managing radiation injury in patients with lung cancer. A multicenter, open-label, randomized clinical trial randomly assigned patients with lung cancer to receive either CKI (20 mL/d for at least 4 weeks) integrated with curative RT (RT + CKI group; n=130) or RT alone (control group; n=130). The primary outcome was the incidence of grade ≥2 radiation-induced lung injury (RILI) in the lungs, esophagus, or heart. Secondary outcomes included patient-reported symptoms, quality of life, objective response rate (ORR), and toxic effects. During the 16-week trial, the RT + CKI group had a significantly lower incidence of grade ≥2 RT-related injury than the control group (12.3% [n=16] vs 23.1% [n=30]; P=.02). Compared with the control group, the RT + CKI group experienced a significant decrease in moderate-to-severe symptoms of fatigue, cough, and pain (P<.001 for the treatment and time interaction term); significantly less physical symptom interference (P=.01); and significantly better quality of life by the end of the trial (P<.05). No statistically significant difference in ORR was found. Adverse reactions associated with CKI were rare. This study demonstrated low toxicity of CKI and its effectiveness in patients with lung cancer in reducing the incidence of grade ≥2 RILI and symptom burden, improving patients' quality of life.